Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 11, 2012, Pages 2827-2837

  Vopenkova, Katerina ^a   Mollova, Klara ^a   Buresova, Ivana ^a   Michalek, Jaroslav ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cancer immunotherapy; Cytotoxicity; Dendritic cell; Interleukin 12; Maturation; Migration

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4;

ARTICLE; CELL CULTURE; CELL MOTION; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MONOCYTE; NEOPLASM; T LYMPHOCYTE; TUMOR CELL LINE;

BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; MONOCYTES; NEOPLASMS; T-LYMPHOCYTES;

EID: 84868144307     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01614.x     Document Type: Article

References (47)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392: 245-52.
2. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007; 449: 419-26.
3. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003; 15: 138-47.
4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005; 5: 296-306.
5. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10: 475-80.
6. Berger TG, Strasser E, Smith R, et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods. 2005; 298: 61-72.
7. Anguille S, Smits E, Cools N, et al. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009; 7: 109.
8. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 2010; 59: 1573-82.
9. Schuler G. Dendritic cells in cancer immunotherapy. Eur J Immunol. 2010; 40: 2123-30.
10. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007; 56: 1513-37.
11. Skalova K, Mollova K, Michalek J. Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine. 2010; 28: 5153-60.
12. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-9.
13. Bürdek M, Spranger S, Wilde S, et al. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med. 2010; 8: 90.
14. Curti A, Trabanelli S, Onofri C, et al. Indoleamine 2, 3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica. 2010; 95: 2022-30.
15. Soleimani A, Berntsen A, Svane IM, et al. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009; 70: 481-9.
16. Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, et al. A full scale comparative study of methods for generation of functional den- dritic cells for use as cancer vaccines. BMC Cancer. 2007; 7: 119.
17. Adamson L, Palma M, Choudhury A, et al. Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production. Scand J Immunol. 2009; 69: 529-36.
18. Ocadlíková D, Zahradová L, Kovárová L, et al. The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells. Klin Onkol. 2009; 22: 67-72.
19. Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009; 49: 124-32.
20. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004; 64: 5934-7.
21. Zobywalski A, Javorovic M, Frankenberger B, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007; 5: 18.
22. Yang D, Kim M, Hong CY, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010; 89: 795-801.
23. Felzmann T, Hüttner KG, Breuer SK, et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother. 2005; 54: 769-80.
24. Lehner M, Stilper A, Morhart P, et al. Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma). J Leukoc Biol. 2008; 83: 883-93.
25. Ten Brinke A, van Schijndel G, Visser R, et al. Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8 + cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother. 2010; 59: 1185-95.
26. Kim S, Kim HO, Kim HJ, et al. Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic: polycytidylic acid and soluble CD40 ligand for clinical application. Clin Exp Immunol. 2008; 154: 365-74.
27. Huang X, Fan Z, Borowski L, et al. Dendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapy. PLoS ONE. 2010; 5: e12936.
28. Ten Brinke A, Karsten ML, Dieker MC, et al. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine. 2007; 25: 7145-52.
29. Hovden A, Karlsen M, Jonsson R, et al. Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol. 2011; 12: 2.
30. Kaka AS, Foster AE, Weiss HL, et al. Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother. 2008; 31: 359-69.
31. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000; 1: 311-6.
32. Boullart ACI, Aarntzen EH, Verdijk P, et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother. 2008; 57: 1589-97.
33. Pacheco R, Martinez-Navio JM, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA. 2005; 102: 9583-8.
34. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood. 2002; 100: 1362-72.
35. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006; 55: 819-29.
36. Dohnal A, Witt V, Hügel H, et al. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007; 9: 755-70.
37. Hersey P, Halliday GM, Farrelly ML, et al. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother. 2008; 57: 1039-51.
38. Verdijk P, Aarntzen EH, Lesterhuis WJ, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009; 15: 2531-40.
39. Yi Q, Szmania S, Freeman J, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010; 150: 554-64.
40. Sharma A, Koldovsky U, Xu S, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012; doi:10.1002/cncr.26734.
41. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007; 67: 1842-52.
42. Kim JY, Kim YJ, Kim JS, et al. Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy. Cancer Lett. 2011; 313: 226-34.
43. Dilioglou S, Cruse JM, Lewis RE. Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp Mol Pathol. 2003; 75: 217-27.
44. Aerts-Toegaert C, Heirman C, Tuyaerts S, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol. 2007; 37: 686-95.
45. Prechtel AT, Turza NM, Theodoridis AA, et al. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol. 2007; 178: 5454-64.
46. Jonuleit H, Kühn U, Müller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997; 27: 3135-42.
47. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83 + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. 1998; 161: 2804-9.